Chimeric Polypeptide for Lafora Disease Glycogen Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective methods for clearing glycogen build-up and treating glycogen storage diseases, particularly Lafora Disease, which is characterized by severe neurodegeneration and accumulation of insoluble glycogen in cells, leading to fatal outcomes.
Innovation Solution
A chimeric polypeptide comprising an alpha-amylase polypeptide and an internalizing moiety, such as an antibody or antigen binding fragment, is used to target and degrade glycogen accumulation in cells, specifically designed to penetrate cellular membranes via equilibrative nucleoside transporters, thereby reducing glycogen levels in muscle, liver, and neuronal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiepileptic medications are used to manage seizures and myoclonus, then symptom control is improved, but glycogen accumulation is not reduced and disease progression continues
Solution Approach 1:
The patent uses an internalizing moiety (antibody or antigen-binding fragment) as an intermediary to deliver the alpha-amylase enzyme into cells. This mediator enables the enzyme to cross cellular membranes and reach the cytoplasm where glycogen accumulation occurs, thereby addressing the core problem of glycogen clearance while maintaining symptom control
2Device complexity
If no specific treatment is applied, then current treatment simplicity is maintained, but glycogen build-up persists leading to neurodegeneration and fatal outcomes
Solution Approach 1:
The patent changes the parameter of enzyme delivery by modifying the alpha-amylase enzyme through fusion with an internalizing moiety. This parameter change enables the enzyme to cross cellular membranes and effectively reduce glycogen accumulation, thereby preventing neurodegeneration without requiring complex multi-step treatment protocols
3Device complexity
If alpha-amylase is administered without internalizing moiety, then enzyme simplicity is maintained, but cellular membrane penetration is insufficient to clear cytoplasmic glycogen
Solution Approach 1:
The patent merges the alpha-amylase enzyme with an internalizing moiety (antibody or antigen-binding fragment) to create a chimeric polypeptide. This combination preserves the enzyme's glycogen-degrading function while adding membrane-penetrating capability, thereby achieving reliable glycogen clearance in cytoplasm without significantly increasing structural complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric polypeptide effectively reduces glycogen accumulation in affected cells, demonstrating potential as a therapeutic approach for treating glycogen storage diseases by enhancing glycogen clearance and improving clinical outcomes for patients with Lafora Disease.
Implementation Method 1
specifically designed to penetrate cellular membranes via equilibrative nucleoside transporters
Implementation Method 2
an alpha-amylase polypeptide... to target and degrade glycogen accumulation in cells
Data Source
AI summary
In certain embodiments, the present disclosure provides compositions and methods for treating Lafora Disease.